drugset / Trial / NCT05902962
SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects
NaSingle-groupOpen-labelTreatment
Summary
A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
Timeline
- Start
- 2023-04-20
- Primary completion
- 2025-08-08
- Completion
- 2025-08-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VP-001 | Oligonucleotide (other) | — | Intravitreal |